PNPLA3 gene in liver diseases

详细信息    查看全文

• 作者：Eric Tré ; po¹ ; ² ; ³ ; ^{etrepo@ulb.ac.be" class="auth_mail" title="E-mail the corresponding author} ; Stefano Romeo⁴ ; ⁵ ; ⁶ ; Jessica Zucman-Rossi¹ ; ⁷ ; ⁸ ; ⁹ ; Pierre Nahon¹ ; ⁸ ; ¹⁰
• 关键词：GWAS ; genome-wide association studies ; CHC ; chronic hepatitis C ; SNP ; single nucleotide polymorphism ; HCV ; hepatitis C virus ; PNPLA3 ; patatin-like phospholipase domain containing 3 ; NAFLD ; nonalcoholic fatty liver disease ; ALT ; alanine aminotransferase ; BMI ; body mass index ; HCC ; hepatocellular carcinoma ; NASH ; nonalcoholic steatohepatitis ; ALD ; alcoholic liver disease ; OR ; odds ratio ; HIV ; human immunodeficiency virus ; TG ; triglycerides ; WT ; wild type ; VLDL ; very low density lipoproteins ; MAF
• 刊名：Journal of Hepatology
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：65
• 期：2
• 页码：399-412
• 全文大小：1173 K

文摘

Genome-wide association studies (GWAS) in the field of liver diseases have revealed previously unknown pathogenic loci and generated new biological hypotheses. In 2008, a GWAS performed in a population-based sample study, where hepatic liver fat content was measured by magnetic spectroscopy, showed a strong association between a variant (rs738409 C>G p.I148M) in the patatin-like phospholipase domain containing 3 (PNPLA3) gene and nonalcoholic fatty liver disease. Further replication studies have shown robust associations between PNPLA3 and steatosis, fibrosis/cirrhosis, and hepatocellular carcinoma on a background of metabolic, alcoholic, and viral insults. The PNPLA3 protein has lipase activity towards triglycerides in hepatocytes and retinyl esters in hepatic stellate cells. The I148M substitution leads to a loss of function promoting triglyceride accumulation in hepatocytes. Although PNPLA3 function has been extensively studied, the molecular mechanisms leading to hepatic fibrosis and carcinogenesis remain unclear. This unsuspected association has highlighted the fact that liver fat metabolism may have a major impact on the pathophysiology of liver diseases. Conversely, alone, this locus may have limited predictive value with regard to liver disease outcomes in clinical practice. Additional studies at the genome-wide level will be required to identify new variants associated with liver damage and cancer to explain a greater proportion of the heritability of these phenotypes. Thus, incorporating PNPLA3 and other genetic variants in combination with clinical data will allow for the development of tailored predictive models. This attractive approach should be evaluated in prospective cohorts.